Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. (Q40362170)

19 September 2017

title

Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. (English)

1 reference

19 September 2017

F Servida

1

1 reference

19 September 2017

D Soligo

2

1 reference

19 September 2017

D Delia

3

1 reference

19 September 2017

C Henderson

4

1 reference

19 September 2017

C Brancolini

5

1 reference

19 September 2017

L Lombardi

6

1 reference

19 September 2017

G Lambertenghi Deliliers

7

1 reference

19 September 2017

language of work or name

1 reference

1 December 2005

1 reference

19 September 2017

1 reference

19 September 2017

volume

19

1 reference

19 September 2017

issue

12

1 reference

19 September 2017

page(s)

2324-2331

1 reference

The proteasome: a suitable antineoplastic target

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Catalytic mechanism of the 20S proteasome of Thermoplasma acidophilum revealed by X-ray crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Activation of the cell death program by inhibition of proteasome function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Therapeutic anti-cancer targets upstream of the proteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

The proteasome: a novel target for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Clinical update: proteasome inhibitors in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl cells sensitive and resistant to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Anticancer therapy targeting the apoptotic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Clinical update: proteasome inhibitors in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Analysis of gene expression in neural cells subject to chronic proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Programmed cell death and the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Caspase activation and apoptosis in response to proteasome inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Dephosphorylation of Bcl-2 by protein phosphatase 2A results in apoptosis resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Preferential induction of apoptosis for primary human leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

The role of the ubiquitin-proteasome pathway in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

7 January 2021

A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

7 January 2021

Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

7 January 2021

Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

7 January 2021

Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

7 January 2021

Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

7 January 2021

Apoptosis induced in L1210 leukaemia cells by an inhibitor of the chymotrypsin-like activity of the proteasome

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

7 January 2021

Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

7 January 2021

Treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403987

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403987

1 reference

Dimensions Publication ID

19 September 2017

1010016285

0 references

1 reference